IL198102A0 - Use of an il-21 polypeptide in the manufacture of a medicament for modulating an il-10 deficiency, or a disorder associated therewith in a mammal - Google Patents

Use of an il-21 polypeptide in the manufacture of a medicament for modulating an il-10 deficiency, or a disorder associated therewith in a mammal

Info

Publication number
IL198102A0
IL198102A0 IL198102A IL19810209A IL198102A0 IL 198102 A0 IL198102 A0 IL 198102A0 IL 198102 A IL198102 A IL 198102A IL 19810209 A IL19810209 A IL 19810209A IL 198102 A0 IL198102 A0 IL 198102A0
Authority
IL
Israel
Prior art keywords
mammal
polypeptide
modulating
medicament
deficiency
Prior art date
Application number
IL198102A
Other languages
English (en)
Original Assignee
Wyeth Corp
Deborah A Young
Mary Collins
Elaine Y Chin
Mayra Senices
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Deborah A Young, Mary Collins, Elaine Y Chin, Mayra Senices filed Critical Wyeth Corp
Publication of IL198102A0 publication Critical patent/IL198102A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL198102A 2003-03-21 2009-04-07 Use of an il-21 polypeptide in the manufacture of a medicament for modulating an il-10 deficiency, or a disorder associated therewith in a mammal IL198102A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45692003P 2003-03-21 2003-03-21
PCT/US2004/008833 WO2004084835A2 (en) 2003-03-21 2004-03-22 Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor

Publications (1)

Publication Number Publication Date
IL198102A0 true IL198102A0 (en) 2009-12-24

Family

ID=33098171

Family Applications (1)

Application Number Title Priority Date Filing Date
IL198102A IL198102A0 (en) 2003-03-21 2009-04-07 Use of an il-21 polypeptide in the manufacture of a medicament for modulating an il-10 deficiency, or a disorder associated therewith in a mammal

Country Status (17)

Country Link
US (1) US20060159655A1 (https=)
EP (1) EP1608315A4 (https=)
JP (1) JP2006523682A (https=)
KR (1) KR20060015482A (https=)
CN (1) CN1849131A (https=)
AU (1) AU2004224277A1 (https=)
BR (1) BRPI0408523A (https=)
CA (1) CA2518854A1 (https=)
CO (1) CO5611161A2 (https=)
CR (1) CR7994A (https=)
EC (1) ECSP056027A (https=)
IL (1) IL198102A0 (https=)
MX (1) MXPA05010035A (https=)
NO (1) NO20054343L (https=)
RU (1) RU2005132458A (https=)
WO (1) WO2004084835A2 (https=)
ZA (1) ZA200507235B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7314623B2 (en) * 2002-07-15 2008-01-01 Wyeth Methods and compositions for modulating T helper (Th) cell development and function
NZ542306A (en) 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
EP1670501A2 (en) * 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1753458A4 (en) * 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
RU2007102287A (ru) * 2004-08-05 2008-09-10 Вайет (Us) Антагонисты активности рецептора интерлейкина-21
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CA2604222A1 (en) * 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
WO2007111714A2 (en) * 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
WO2007114861A2 (en) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
US7883700B2 (en) 2007-12-07 2011-02-08 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
WO2009100035A2 (en) * 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
PE20100141A1 (es) * 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
US8178097B2 (en) * 2008-05-23 2012-05-15 Wyeth Llc Methods of treatment utilizing binding proteins of the interleukin-21 receptor
US20100075329A1 (en) * 2008-09-23 2010-03-25 O'toole Margot Methods for predicting production of activating signals by cross-linked binding proteins
CA2740077A1 (en) * 2008-10-08 2010-04-15 Cambridge Enterprise Limited Methods and compositions for diagnosis and treatment
CA2798739A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
EP3502236B1 (en) * 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
AU2016341529B2 (en) 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
US12600757B2 (en) 2017-04-07 2026-04-14 Bioniz Therapeutics, Inc. Peptides inhibiting gamma-c-cytokine activity and methods of use
KR102454376B1 (ko) * 2018-07-04 2022-10-17 서울대학교산학협력단 신경손상의 면역세포치료
CN120365435A (zh) 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
CA3137971A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
JP7713393B2 (ja) 2019-06-21 2025-07-25 イミュニティーバイオ インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
EP4143231A1 (en) 2020-04-29 2023-03-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
EP4146669A4 (en) * 2020-05-08 2024-06-05 Alastin Skincare, Inc. Compositions and methods for modulating inflammation and wound healing
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4157460A1 (en) 2020-06-01 2023-04-05 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4507711A1 (en) 2022-04-13 2025-02-19 ImmunityBio, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
CN120813605A (zh) * 2023-01-06 2025-10-17 泰温治疗私人有限公司 抗原结合分子

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010025022A1 (en) * 1997-11-26 2001-09-27 Kikly Kristine Kay Hnovilr
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
EP1082433A4 (en) * 1998-05-29 2003-01-02 Human Genome Sciences Inc Interleukins 21 and 22
AU5104799A (en) * 1998-08-04 2000-02-28 Regeneron Pharmaceuticals, Inc. Novel orphan cytokine receptors
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US20020090680A1 (en) * 1999-05-18 2002-07-11 Millennium Pharmaceuticals, Inc. Novel IL-9/IL-2 receptor-like molecules and uses thereof
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
ES2629395T3 (es) * 2001-10-04 2017-08-09 Genetics Institute, Llc Métodos y composiciones para modular la actividad de la interleucina-21
ES2334338T3 (es) * 2001-11-05 2010-03-09 Zymogenetics, Inc. Antagonistas de il-21.
CA2481304A1 (en) * 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
DK1531850T3 (da) * 2002-06-07 2012-06-04 Zymogenetics Inc Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
US7314623B2 (en) * 2002-07-15 2008-01-01 Wyeth Methods and compositions for modulating T helper (Th) cell development and function
NZ542306A (en) * 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
EP1753458A4 (en) * 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
RU2007102287A (ru) * 2004-08-05 2008-09-10 Вайет (Us) Антагонисты активности рецептора интерлейкина-21
US7533965B2 (en) * 2005-03-07 2009-05-19 Eastman Kodak Company Apparatus and method for electrostatically charging fluid drops
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis

Also Published As

Publication number Publication date
WO2004084835A3 (en) 2006-05-26
US20060159655A1 (en) 2006-07-20
WO2004084835A2 (en) 2004-10-07
CA2518854A1 (en) 2004-10-07
RU2005132458A (ru) 2006-03-20
KR20060015482A (ko) 2006-02-17
BRPI0408523A (pt) 2006-03-21
EP1608315A2 (en) 2005-12-28
ECSP056027A (es) 2006-09-18
MXPA05010035A (es) 2005-11-17
AU2004224277A1 (en) 2004-10-07
CN1849131A (zh) 2006-10-18
ZA200507235B (en) 2007-03-28
NO20054343L (no) 2005-11-24
EP1608315A4 (en) 2008-07-16
JP2006523682A (ja) 2006-10-19
CR7994A (es) 2006-10-17
NO20054343D0 (no) 2005-09-20
CO5611161A2 (es) 2006-02-28

Similar Documents

Publication Publication Date Title
IL198102A0 (en) Use of an il-21 polypeptide in the manufacture of a medicament for modulating an il-10 deficiency, or a disorder associated therewith in a mammal
IL181964A0 (en) Medicaments comprising carbonyl compounds, and the use thereof
PT1594867E (pt) Fenilacetamidas e sua utilização como moduladores de glucocinase
ZA200706254B (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
IL162669A0 (en) Antichlinergic agents, method for producing the same and use thereof as medicaments
IL178402A0 (en) 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof
EP1605788B8 (en) Respirator
IL162316A0 (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition t
AP2005003416A0 (en) Multi-carbide material manufacture and use.
EP1731139A4 (en) PHARMACEUTICAL PREPARATION OF THE S / O TYPE AND MANUFACTURING METHOD THEREFOR
ZA200701496B (en) Post-foaming dental mousse and methods utilizing the same
IL177223A (en) Tat complexes, vaccines containing them and their uses
GB0421810D0 (en) Improved laminates and the manufacture thereof
AU2004200403A1 (en) The trolley tamer
MXPA03008815A (es) Agente terapeutico para sintomas irritantes de vejiga asociados con hiperplasia prostatica benigna.
AU2002331114A1 (en) Tetrahydroisochinolines, their production and the use thereof as analgesics
GB0312340D0 (en) Improved game and aricle for use with the game
PL377631A1 (pl) Triazolopirymidyny, ich wytwarzanie i ich zastosowanie do zwalczania szkodliwych grzybów oraz zawierające je środki
AU2003903279A0 (en) The safe sleeper
GB0307780D0 (en) Wheel with two half-frames
GB0212233D0 (en) The chair pinnie
AU2723P (en) Sunbel-apu Calibrachoa hybrid
HK1107099A (en) Substituted adenines and the use thereof
AU2004902573A0 (en) The 'POWERWEEDER'
AU2004900232A0 (en) "The Multi-GMT" timepiece